Loading company
Immucell Corp.
ICCC · Nasdaq · ·
$9.83-2.6%Sep 29 close
- 1M
- -1.1%
- 6M
- +52.9%
- 1Y
- +57.3%
- 5Y
- +2.1%
ICCC · Nasdaq · ·
$9.83-2.6%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $7.2M | $6.4M | +11.50% |
| Profit | $1.8M | $501.9K | +265.56% |
| Profit per share | $0.20 | $0.06 | +233.33% |
| Free Cash Flow | $2.3M | $1.4M | +57.99% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Immucell Corp. has no earnings call transcript available.
“We saw an acceleration of our distributors’ out-the-door volume growth to 28% in the second quarter of 2026, up from 21% in the first quarter of 2026,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
ImmuCell Corporation (Nasdaq: ICCC) is an animal-health biologics company that operates in the fast-growing market for calf health solutions. It develops, manufactures and commercializes the First Defense® line of products that provides Immediate Immunity™ through colostrum-derived, orally delivered antibodies against the principal viral and bacterial causes of scours. Scours (neonatal calf diarrhea) is one of the most prevalent and deadly diseases in neonatal calves worldwide. Press releases and other information about the Company are available at: http://www.immucell.com/investors .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Immucell Corp.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.